Henoch-Schonlein Purpura (HSP) is a systemic IgA-mediated vasculitis of small vessels common in children. The natural history of HSP is generally self-limiting, however, one third of patients experience recurrence of symptoms showing refractory courses. Our objective was to generate a systematic review of the use of dapsone in refractory HSP. A literature search of PubMed and MEDLINE databases was performed and 13 articles were finally identified published until June 14, 2018. The most common clinical feature was a palpable rash which was seen in all patients (100%) and joint pain was the following (69.2%). Treatment response within 1-2 days was observed in 6 of the 26 (23.1%) patients and 17 (65.4%) patients responded within 3 to 7 days. Relapse after discontinuation of treatment was reported in 17 patients (65.4%), whereas 3 patients (11.5%) reported no relapse of symptoms. Four of the 26 (15.4%) patients reported adverse effects of dapsone. The adverse effects included arthralgia (7.7%), rash (7.7%) and dapsone hypersensitivity syndrome (3.8%). This systematic study suggests that dapsone has an effect on refractory HSP. To determine the standard dosage of dapsone at initial treatment or tapering of treatment in HSP patients and evaluate whether dapsone has a significant benefit compared with steroids or other medication, multicenter, randomized placebo controlled clinical trials are necessary.
Introduction
Henoch-Schonlein Purpura (HSP) is a systemic IgA-mediated vasculitis of small vessels that is common in children. The major clinical features of HSP are palpable purpura, arthritis, abdominal pain and nephritis. 1) The natural history of HSP is generally self-limiting, however, one third of patients experience recurrence of symptoms showing refractory courses. 2) Patients with renal disease are more likely to have recurrences and the long-term prognosis for HSP is related to nephritis. [1] [2] [3] [4] [5] However, the treatment for HSP is not established. Steroids can manage symptoms of abdominal pain but are not suitable for the prevention of nephropathy. 2) Joint pain is managed with non-steroidal anti-inflammatory drugs and steroids for severe cases. 2) Cutaneous symptoms respond to steroids and dapsone. 2) Some cases reported immunosuppressive therapy could be considered for HSP with nephropathy, however, treatment of nephritis remains conroversial. 2) Treatment with steroids and immunosuppressive therapy such as cyclophosphamide, cyclosporine and azathioprine is benefial on HSP nephritis. 1,2,6) Some reports showed colchicine and dapsone may be useful in chronic HSP. 6) Among the diverse armamentarium of therapeutic options, dapsone has been used in several severe cases. Although dapsone is not considered as a standard treatment for HSP, the symptoms of purpuric rash, abdominal pain and arthritis in HSP respond to treatment with dapsone. 7) Dapsone, known as an antileprosy drug, has anti-oxidant scavenger effects and may suppress the production of toxic free radicals by neutrophils. It inhibits prostaglandin D2 production and synthesis of IgG and IgA antibodies. 8) It also inhibits IgA-neutrophil interactions, which may explain the potential efficacy of dapsone in the management of HSP. 7, 9) Therefore, in the absence of clinical trials, the aim of this systematic review was to provide characteristics of dapsone use in refractory HSP.
A c c e p t e d A r t i c l e

Materials and methods
Search strategy
We searched MEDLINE through the PubMed website for articles of HSP treated with dapsone published until June 14, 2018. The search terms were: "Purpura" AND "Dapsone".
Two of the reviewers (SHH and YHJ) screened the articles by investigating the titles, abstracts, and the full texts.
The exclusion criteria were as following: 10) We excluded 86 articles after investigating abstracts and full texts according to the exclusion criteria stated above; 60 were not about either HSP or dapsone, 13 were not written in English, 11 were review articles, 2 were animal studies. Of the remaining 13 articles, 1 article that was published in 1973 was excluded because we considered it too old to be reliable. After about 2 years, another reviewer (YHJ) conducted the following search which found 10 more articles published until June 14, 2018. Of those 10 articles, 9 articles not related to either HSP or dapsone were excluded. Finally, 13 articles eligible to our systematic review were identified (5 case reports, 3 case series and 5 letters). The detailed process of article selection is presented in Figure 1 .
A c c e p t e d
A r t i c l e 6 patients (23.1%) and all of them but one also reported hematuria. Patients with proteinuria were all under 15 years old. Five patients had diarrhea, and all of them had joint pain. Every patient with vomiting and diarrhea complained of abdominal pain. Three patients (11.5%) had rectal bleeding, and they were all were under 15 years old. The bleeding was associated with hematuria and joint pain. Only 1 patient had a swollen testicle. Bullae and ulcers were simultaneously seen in 2 patients (8.0%). Table 2 summarizes the results of twenty-six dapsone-treated HSP patients according to age, sex, the dosage of dapsone, course of symptoms and adverse effects. We analyzed specific dapsone dosages, clinical outcomes and adverse effects of dapsone in this section.
Dosage of dapsone
All patients were grouped based on their age. Group 1 had patients' age ranging from 11 to 56 and group 2 included patients from age 2 to 10. Age was factored into the dosing strategies of dapsone and the results due to different strategies from the two groups are summarized in Table 3 . The doses given to each patient with HSP were very different. In group 1, daily doses of 50-100 mg were given, and in group 2, daily doses of 0.50-1.30 mg per kg were given.
In group 1, 11 patients took 100 mg dapsone per day and 4 patients took 50 mg per day. One case in group 1, which is not shown in Table 3 , received a prescribed dapsone dose in units of milligrams per kilogram. Another study in group 1 started with 75mg of dapsone every day, and this dosage was increased to 100 mg after 3 days. In group 2, 4 of 8 patients took 1 mg of dapsone per kg and the other 4 patients were given different doses each: 0.5, 0.75, 1.25 and 1.30 mg/kg.
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Course of symptoms
Symptom resolution was reported in all cases. In Table 4 , the patient's response to treatment was organized based on treatment response time, the extent of response and time to relapse after discontinuation. Treatment response within 1-2 days was observed in 6 of the 26 (23.1%) patients. Within 3 to 7 days, 17 (65.4%) patients responded to the treatment. Three patients (11.5%) showed response after the first week. In the immediate relapse group, all but one patient showed an immediate recurrence of symptoms after discontinuation and one patient reported relapse of symptoms 4-5 days after discontinuation. Of the 4 patients that experienced relapse during the first year, one patient reported an occasional relapse of symptoms during the first 10 months, and the other 3 patients in the group showed no recurrence within 6, 9 and 12 months after discontinuation of treatment. Of the 3 patients who showed relapse after one year, one patient reported purpura and mild arthralgia after 3 years. The other 2 patients had disease-free periods of 1.5 and 6 years ( Table 4 ).
A c c e p t e d A r t i c l e
Adverse effects of dapsone
Four of the 26 (15.4%) patients reported adverse effects of dapsone. Summary of the adverse effects are presented in Table 6 . The adverse effects of dapsone for patients with HSP were arthralgia (7.7%), dapsone hypersensitivity syndrome (3.8%), rash (7.7%), gastrointestinal symptoms (3.8%) and dizziness (3.8%). Only one patient reported multiple adverse effects including arthralgia, rash and GI symptoms.
Discussion
HSP is a systemic IgA-mediated vasculitis characterized by palpable cutaneous purpura, arthritis, abdominal pain, gastrointestinal bleeding and nephritis. 1) Although HSP is usually a self-limiting disease, one report showed that 33% of patients will experience a relapse. 19) The aim of drug therapy in HSP is rapid symptomatic relief because the symptoms of HSP are generally self-limiting with the exception of renal disease, which might be developed to longterm complications. 1) Steroids are considered as the mainstay of treatment because they seem to have a relief effect on abdominal 20, 21) and joint pain. 21) In one study of 417 patients, corticosteroids and non-steroidal anti-inflammatory drugs were commonly prescribed. 22) One report showed that azathioprine can be used in recurrent HSP. 23) Factor XIII may have diagnostic value in patients with severe gastrointestinal symptoms without cutaneous rash and infusion of activated factor XIII can be an adjunctive therapy in such patients. 24) Similarly, factor XIII and intravenous immunoglobulin therapy can be effective in HSP patients with severe abdominal symptoms. 25, 26) Despite these various attempts, there is no standardized treatment for recurrent HSP.
Corticosteroids have various side-effects and there have been corticosteroid-resistant patients with HSP, who were treated by mizoribine or cyclosporine A. 27, 28) Drugs such as A c c e p t e d A r t i c l e azathioprine, factor XIII, and intravenous immunoglobulin are either expensive or exhibit potential severe side effects. In contrast, dapsone is safe can be prescribed as pills. Yet, only a few cases with recurrent HSP were treated with dapsone.
However, the use of dapsone in HSP seems to be relatively unfamiliar to clinicians compared to steroids although the first case of HSP treated with dapsone was reported in 1983. 29) Dapsone is an antileprosy drug and can be used for dermatological diseases which are associated with deposition of antibodies and accumulation of neutrophils. 30) Dapsone can be considered as an alternative, especially in relapsed HSP, in consideration that HSP is an IgA-mediated vasculitis and IgA-neutrophil interaction could be inhibited by dapsone. 7, 9) In leprosy, World Health Organization (WHO) regimens are the standard treatment. The WHO recommends using dapsone 100 mg daily for 6 months in paucibacillary leprosy and 100 mg daily for at least 2 years and up to smear negativity in multibacillary leprosy. 30) One study showed that peak serum concentrations of dapsone of 1.10 to 2.33 mg/L were reached within 0.5 to 4 hours after 100 mg were orally administered in 25 healthy volunteers. 31) However, in severe leprosy patients, absorption could be decreased. 32) In leprosy, the therapeutic range of dapsone is 0.5 to 5 mg/L and the adverse effect of dapsone is rare if dapsone is below 5 mg/L in plasma. 33) The most common adverse effect is a methemoglobinemia, which is usually not a serious problem except at doses exceeding 200 mg/day. 34) Hemolysis and frank anemia is another side effect which is well-known. 35) Increasing age and the daily dose of dapsone were related to increased magnitude of hemolysis in dapsone therapy. 35) So, it is recommended not to exceed 1.5 mg/kg body weight or 100 mg in normal healthy persons. 36) Agranulocytosis is a fatal adverse effect of dapsone. 37 Another rare side effect is a hypersensitivity syndrome called dapsone syndrome which is characterized by fever, rash and internal organ involvement. 38, 39) Other side effects include A c c e p t e d A r t i c l e neurotoxicity such as peripheral neuropathy (rare, typically at doses exceeding 300 mg/day) and psychosis (rare, at a dose below 100 mg/day), which is dose-independent. [40] [41] [42] [43] In our reviewed patients, none of the patients' treatment exceeded 100 mg/day or 1.5 mg/kg. One patient who stopped dapsone because of dizziness at 100 mg/day didn't report dizziness at 150 mg/day after the recurrence of HSP. This means the side effect of dapsone is somewhat unpredictable and dose-independent. However, although many side effects of dapsone may be dose-independent, to minimize the adverse effect, the dose should not exceed 100 mg/day or 1.5 mg/kg. In our reviewed patients, discontinuation of treatment without tapering seems to be related to relapse because 15 patients reported prompt recurrence whereas the tapering group reported fewer relapses.
This study has a limitation that only 26 patients were reviewed. Because of the small number of patients, it is difficult to explain the use of dapsone in detail such as how to taper out. In our reviewed patients, 19.0% of the patients didn't need tapering; however, because of the small number of patients, our results cannot confirm what percentage of people doesn't need tapering and what are the indications for tapering.
To best of our knowledge, this is the first systematic review summarizing dapsone efficacy in HSP. Since there are several side effects which should be noted, most patients with recurrent disease or non-responsible to previous treatments should be acknowledged about the side effects by clinicians and considered to be started on dapsone depending on the risk and benefit. However, our study will increase the awareness that dapsone is an effective treatment for recurrent HSP patients. To determine the standard use or dosage of dapsone as a treatment option at the time of initiation or tapering of treatment in refractory HSP patients and to evaluate whether dapsone has a significant benefit compared to steroids or other medication, multicenter, randomized and placebo-controlled clinical trials are necessary. No relapse (n=3) --- 1 One with prednisone 2mg/kg/day 2 With the most beneficial effect on the skin rash 3 One with purpura resolved gradually with the combination of factor XII 4 One with no information about the exact time of the disappearance of purpura 5 Prompt relapse (n=9), Relapse after 4-5 days (n=1) 6 Occasional relapse over 10 months (n=1), No recurrence for 9 months (n=1), no recurrence for 6 months, No recurrence for 12 months with 50mg as maintenance therapy (n=1) 7 Purpura and mild arthralgia without abdominal pain in 3 years (n=1), 6 year disease free (n=1), 1.5 year disease free (n=1)
A c c e p t e d A r t i c l e 6 Adverse effects of using dapsone for patients with HSP 
